(vianews) - shares of erytech pharma (cac 40: eryp.pa) slid by a staggering 20.69% in 10 sessions from €0.87 to €0.69 at 13:57 est on thursday, after three consecutive sessions in a row of losses. cac 40 is rising 0.85% to €6,944.48, following the last session's downward trend.
erytech pharma's last close was €0.68, 70.04% below its 52-week high of €2.26.
about erytech pharma
erytech pharma s.a., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in france and the united states. its lead product candidate is eryaspase, which is in phase 3 clinical development for the treatment of second-line pancreatic cancer, and in phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. the company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. the company was incorporated in 2004 and is headquartered in lyon, france.
earnings per share
as for profitability, erytech pharma has a trailing twelve months eps of €-3.99.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, erytech pharma's stock is considered to be overbought (>=80).
volatility
erytech pharma's last week, last month's, and last quarter's current intraday variation average was a negative 4.28%, a negative 1.49%, and a positive 6.18%.
erytech pharma's highest amplitude of average volatility was 4.78% (last week), 4.27% (last month), and 6.18% (last quarter).
more news about erytech pharma (eryp.pa).